Caxton Associates LLP Acquires Shares of 3,352 DaVita Inc. $DVA

Key Points

• Caxton Associates LLP acquired a $513,000 stake in DaVita Inc., purchasing 3,352 shares in the first quarter.
• Goldman Sachs increased its stake in DaVita by 19.1%, owning 179,140 shares valued at approximately $27.4 million after the purchase.
• DaVita's stock has a consensus rating of "Reduce" with a target price of $158.00, following recent price adjustments from several brokerages.

Caxton Associates LLP purchased a new position in DaVita Inc. (NYSE:DVA - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,352 shares of the company's stock, valued at approximately $513,000.

Several other hedge funds have also added to or reduced their stakes in the stock. Goldman Sachs Group Inc. increased its holdings in shares of DaVita by 19.1% during the first quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company's stock valued at $27,403,000 after acquiring an additional 28,739 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in DaVita during the 1st quarter valued at about $364,000. Financial Strategies Group Inc. raised its holdings in DaVita by 21.5% in the first quarter. Financial Strategies Group Inc. now owns 4,688 shares of the company's stock worth $686,000 after buying an additional 831 shares during the last quarter. UniSuper Management Pty Ltd lifted its stake in shares of DaVita by 1.2% in the first quarter. UniSuper Management Pty Ltd now owns 11,645 shares of the company's stock worth $1,781,000 after buying an additional 139 shares in the last quarter. Finally, Petrus Trust Company LTA increased its position in shares of DaVita by 12.7% during the first quarter. Petrus Trust Company LTA now owns 2,047 shares of the company's stock valued at $313,000 after acquiring an additional 230 shares in the last quarter. 90.12% of the stock is owned by institutional investors.

Insider Buying and Selling at DaVita

In other DaVita news, insider James O. Hearty sold 2,351 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the completion of the transaction, the insider owned 26,038 shares of the company's stock, valued at $3,905,700. This trade represents a 8.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 1.50% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on DVA shares. Barclays lowered their target price on shares of DaVita from $169.00 to $160.00 and set an "equal weight" rating on the stock in a research note on Thursday, August 7th. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a research report on Saturday. Bank of America lowered their target price on shares of DaVita from $145.00 to $140.00 and set an "underperform" rating on the stock in a report on Wednesday, September 10th. Finally, Truist Financial set a $148.00 price target on shares of DaVita in a research note on Friday, August 8th. Three equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Reduce" and an average target price of $158.00.

DaVita Trading Down 0.6%

Shares of NYSE DVA traded down $0.78 during trading on Wednesday, hitting $129.34. 81,889 shares of the company were exchanged, compared to its average volume of 842,989. The company has a fifty day moving average price of $137.94 and a 200-day moving average price of $141.27. DaVita Inc. has a 12-month low of $126.07 and a 12-month high of $179.60. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.34 and a current ratio of 1.39. The firm has a market capitalization of $9.25 billion, a PE ratio of 12.71, a P/E/G ratio of 0.94 and a beta of 1.13.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.70 by $0.25. The firm had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.36 billion. DaVita had a net margin of 6.35% and a return on equity of 369.39%. DaVita's revenue was up 6.1% on a year-over-year basis. During the same period in the previous year, the firm earned $2.00 EPS. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. As a group, equities research analysts expect that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.